A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. [electronic resource]
Producer: 20150512Description: 920-7 p. digitalISSN:- 1600-0641
- Adult
- Antiviral Agents -- administration & dosage
- Benzimidazoles -- administration & dosage
- Carbamates -- administration & dosage
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Female
- Genotype
- Half-Life
- Hepacivirus -- drug effects
- Hepatitis C, Chronic -- drug therapy
- Humans
- Male
- Middle Aged
- Polymorphism, Genetic
- RNA, Viral -- blood
- Viral Nonstructural Proteins -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.